Cancer chemotherapy has a high frequency of side eŠects, and patients often experience adverse health eŠects. This review focuses on risk factors and supportive care for the prevention of chemotherapy side eŠects. 1) Drug-induced interstitial lung disease (DILD) is one of the serious adverse events associated with chemotherapy, and this retrospective study investigated the risk of DILD in Japanese patients with lung cancer. Among the 459 patients who received lung cancer chemotherapy from April 2007 to March 2013, 33 (7.2％) developed chemotherapy-associated DILD. Preexisting interstitial lung disease was a risk factor for DILD [odds ratio (OR)＝5.38; 95％ conˆdence interval (CI)＝2.47 11.73]. Early death was observed in 10 of the 33 patients who developed DILD. Epidermal growth factor receptor-tyrosine kinase inhibitor use (OR＝9.26; 95％CI＝1.05 81.96) and two or more prior chemotherapy regimens (OR＝6.95; 95％CI＝1.14 42.35) were identiˆed as poor prognostic factors.
Pemetrexed is administrated on day 1. The incidences of rash in patients who received supplementary corticosteroids at less than 1.5 mg or 1.5 mg or more on day 2 and day 3 was 39.4％ and 17.8％, respectively.
Fig. 2. The EŠects of Corticosteroids in Addition to
Pemetrexed Administration
The incidence of rash in patients who received supplementary corticosteroids at 0 1.5 mg, 1.5 6 mg, and 6 mg or more on day 2 and day 3 was 39.4％, 17.1％, and 16.7％, respectively. Abbreviations: n.s.; not statistically signiˆcant. 
